What is the share price of Alivus Life Sciences Ltd (ALIVUS) today?
The share price of ALIVUS as on 12th June 2025 is ₹1046. The stock prices are volatile and keep changing through the day depending upon various factors and market conditions.What is the return on Alivus Life Sciences Ltd (ALIVUS) share?
The past returns of Alivus Life Sciences Ltd (ALIVUS) share are- Past 1 week: -4.52%
- Past 1 month: -11.25%
- Past 3 months: 4.19%
- Past 6 months: -2.27%
- Past 1 year: 18.36%
- Past 3 years: 119.86%
- Past 5 years: 37.07%
What are the peers or stocks similar to Alivus Life Sciences Ltd (ALIVUS)?
The peers or stocks similar to Alivus Life Sciences Ltd (ALIVUS) include:What is the dividend yield % of Alivus Life Sciences Ltd (ALIVUS) share?
The current dividend yield of Alivus Life Sciences Ltd (ALIVUS) is 0.49.What is the market cap of Alivus Life Sciences Ltd (ALIVUS) share?
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Alivus Life Sciences Ltd (ALIVUS) is ₹12581.75 Cr as of 12th June 2025.What is the 52 week high and low of Alivus Life Sciences Ltd (ALIVUS) share?
The 52-week high of Alivus Life Sciences Ltd (ALIVUS) is ₹1335.10 and the 52-week low is ₹819.05.What is the PE and PB ratio of Alivus Life Sciences Ltd (ALIVUS) stock?
The P/E (price-to-earnings) ratio of Alivus Life Sciences Ltd (ALIVUS) is 25.91. The P/B (price-to-book) ratio is 5.39.Which sector does Alivus Life Sciences Ltd (ALIVUS) belong to?
Alivus Life Sciences Ltd (ALIVUS) belongs to the Health Care sector & Pharmaceuticals sub-sector.How to buy Alivus Life Sciences Ltd (ALIVUS) shares?
You can directly buy Alivus Life Sciences Ltd (ALIVUS) shares on Tickertape. Simply sign up, connect your demat account and place your order.
Alivus Life Sciences Ltd
ALIVUS Share Price
How to use scorecard? Learn more
ALIVUS Performance & Key Metrics
ALIVUS Performance & Key Metrics
No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
---|---|---|
25.91 | 5.39 | 0.49% |
Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
---|---|---|
36.27 | 6.67 | 0.83% |
from 4 analysts
Price Upside
Earnings Growth
Rev. Growth
ALIVUS Company Profile
Alivus Life Sciences Ltd develops and manufactures active pharmaceutical ingredients (APIs) and provides contract development and manufacturing services for chronic therapeutic areas.
ALIVUS Sentiment Analysis
ALIVUS Sentiment Analysis
ALIVUS Stock Summary · May 2025
Alivus Life Sciences demonstrated strong financial performance in Q4 FY'25, achieving a revenue of Rs. 650 crores, a 21.1% year-on-year increase, driven by robust growth across various segments. Despite this success, the company faces challenges such as a rising cash conversion cycle and market erosion of approximately 4% to 4.5%, which could impact future revenue growth. Management remains optimistic about mid-teen volume growth for FY'26, supported by significant capital expenditures of Rs. 550 to Rs. 600 crores aimed at expanding production capacity and enhancing R&D capabilities. While pricing pressures and regulatory concerns pose risks, the company’s net debt-free status and strong cash flow position it well for continued investment and innovation in a dynamic market landscape.
ALIVUS Stock Growth Drivers
ALIVUS Stock Growth Drivers
5Strong Financial Performance
Alivus Life Sciences reported robust financial results for Q4 and FY'25, with revenues reaching Rs.
Expansion and Capital Investment
The company has made significant capital investments, reporting a capital expenditure (CAPEX) of Rs. 166
ALIVUS Stock Challenges
ALIVUS Stock Challenges
4Margin Compression
The company is experiencing a decrease in normalized margins, which are expected to range between
CDMO Segment Performance Challenges
The CDMO segment is facing a soft performance characterized by a price erosion of 4%
ALIVUS Forecast
ALIVUS Forecasts
Price
Revenue
Earnings
ALIVUS Share Price Forecast
ALIVUS Share Price Forecast
All values in ₹
All values in ₹
ALIVUS Company Revenue Forecast
ALIVUS Company Revenue Forecast
All values in ₹ Thousand cr.
All values in ₹ Thousand cr.
ALIVUS Stock EPS (Earnings Per Share) Forecast
ALIVUS Stock EPS (Earnings Per Share) Forecast
All values in ₹
All values in ₹
ALIVUS
ALIVUS
Income
Balance Sheet
Cash Flow
ALIVUS Income Statement
ALIVUS Income Statement
Financial Year | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | TTM | |||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Total Revenue | 0.25 | 886.86 | 1,549.30 | 1,885.98 | 2,137.91 | 2,190.18 | 2,295.25 | 2,421.45 | 2,421.45 | |||||||||
Raw Materials | 0.04 | 633.56 | 668.66 | 948.17 | 977.96 | 1,068.56 | 1,025.21 | 1,704.30 | 1,704.30 | |||||||||
Power & Fuel Cost | 0.00 | 57.81 | 76.75 | 74.19 | 100.92 | 115.60 | 112.46 | |||||||||||
Employee Cost | 0.15 | 106.28 | 142.28 | 149.13 | 168.72 | 180.18 | 258.16 | |||||||||||
Selling & Administrative Expenses | 0.00 | 44.20 | 42.05 | 48.50 | 48.64 | 65.47 | 64.12 | |||||||||||
Operating & Other expenses | 0.08 | -203.15 | 135.61 | 74.11 | 210.91 | 89.11 | 149.02 | |||||||||||
EBITDA | -0.02 | 248.16 | 483.95 | 591.88 | 630.76 | 671.26 | 686.28 | 717.15 | 717.15 | |||||||||
Depreciation/Amortization | 0.00 | 19.26 | 29.37 | 33.39 | 37.88 | 42.09 | 53.45 | 60.61 | 60.61 | |||||||||
PBIT | -0.02 | 228.90 | 454.58 | 558.49 | 592.88 | 629.17 | 632.83 | 656.54 | 656.54 | |||||||||
Interest & Other Items | 0.00 | 0.61 | 33.52 | 87.55 | 27.96 | 0.55 | 1.55 | 2.41 | 2.41 | |||||||||
PBT | -0.02 | 228.29 | 421.06 | 470.94 | 564.92 | 628.62 | 631.28 | 654.13 | 654.13 | |||||||||
Taxes & Other Items | 0.42 | 32.71 | 107.97 | 119.37 | 146.20 | 161.65 | 160.40 | 168.50 | 168.52 | |||||||||
Net Income | -0.44 | 195.58 | 313.09 | 351.57 | 418.72 | 466.97 | 470.88 | 485.63 | 485.61 | |||||||||
EPS | -8.00 | 36.10 | 29.04 | 32.61 | 36.36 | 38.11 | 38.43 | 39.63 | 39.63 | |||||||||
DPS | 0.00 | 0.00 | 0.00 | 0.00 | 21.00 | 42.00 | 22.50 | 5.00 | 0.00 | |||||||||
Payout ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.58 | 1.10 | 0.59 | 0.13 | 0.00 |
ALIVUS Company Updates
Investor Presentation
ALIVUS Stock Peers
ALIVUS Past Performance & Peer Comparison
ALIVUS Past Performance & Peer Comparison
Health CarePharmaceuticals
Valuation
Technical
Forecast
Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
---|---|---|---|
Alivus Life Sciences Ltd | 25.91 | 5.39 | 0.49% |
Sun Pharmaceutical Industries Ltd | 37.12 | 6.04 | 0.95% |
Cipla Ltd | 23.31 | 4.59 | 1.05% |
Dr Reddy's Laboratories Ltd | 19.88 | 3.98 | 0.59% |
ALIVUS Stock Price Comparison
Compare ALIVUS with any stock or ETFALIVUS Holdings
ALIVUS Shareholdings
ALIVUS Promoter Holdings Trend
ALIVUS Promoter Holdings Trend
In last 6 months, promoter holding in the company has almost stayed constant
Pledged promoter holdings is insignificant
ALIVUS Institutional Holdings Trend
ALIVUS Institutional Holdings Trend
In last 3 months, retail holding in the company has almost stayed constant
In last 3 months, foreign institutional holding of the company has almost stayed constant
ALIVUS Shareholding Pattern
ALIVUS Shareholding Pattern
ALIVUS Shareholding History
ALIVUS Shareholding History
Mutual Funds Invested in ALIVUS
Mutual Funds Invested in ALIVUS
In last 3 months, mutual fund holding of the company has almost stayed constant
Top 5 Mutual Funds holding Alivus Life Sciences Ltd
Funds (Top 5) | The rupee value of the stock held by the fund divided by the stock’s market cap Market-cap held | Percentage of the fund’s portfolio invested in the stock Weight | Change in the portfolio weight of the stock over the last 3 months 3M holding change | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months Portfolio rank(3M change) |
---|---|---|---|---|
The rupee value of the stock held by the fund divided by the stock’s market cap 1.0517% | Percentage of the fund’s portfolio invested in the stock 0.46% | Change in the portfolio weight of the stock over the last 3 months 0.26% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 30/112 (+10) | |
The rupee value of the stock held by the fund divided by the stock’s market cap 0.9170% | Percentage of the fund’s portfolio invested in the stock 1.58% | Change in the portfolio weight of the stock over the last 3 months 0.03% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 51/60 (-33) | |
The rupee value of the stock held by the fund divided by the stock’s market cap 0.5291% | Percentage of the fund’s portfolio invested in the stock 0.62% | Change in the portfolio weight of the stock over the last 3 months -0.05% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 52/64 (-6) |
Compare 3-month MF holding change on Screener
smallcases containing ALIVUS stock
smallcases containing ALIVUS stock
Looks like this stock is not in any smallcase yet.
ALIVUS Events
ALIVUS Events
ALIVUS Dividend Trend
No dividend trend available
Dividends
Corp. Actions
Announcements
Legal Orders
ALIVUS Dividend Trend
No dividend trend available
ALIVUS Upcoming Dividends
ALIVUS Upcoming Dividends
No upcoming dividends are available
ALIVUS Past Dividends
ALIVUS Past Dividends
Cash Dividend
Ex DateEx DateOct 17, 2023
Dividend/Share
₹22.50
Ex DateEx Date
Oct 17, 2023
Cash Dividend
Ex DateEx DateMar 24, 2023
Dividend/Share
₹21.00
Ex DateEx Date
Mar 24, 2023
Cash Dividend
Ex DateEx DateSep 15, 2022
Dividend/Share
₹10.50
Ex DateEx Date
Sep 15, 2022
Cash Dividend
Ex DateEx DateNov 22, 2021
Dividend/Share
₹10.50
Ex DateEx Date
Nov 22, 2021
ALIVUS Stock News & Opinions
ALIVUS Stock News & Opinions
Alivus Life Sciences announced that the Board of Directors of the Company at its meeting held on 15 May 2025, inter alia, have recommended the final dividend of Rs 5 per equity Share (i.e. 250%) , subject to the approval of the shareholders.Powered by Capital Market - Live
Net profit of Alivus Life Sciences rose 44.85% to Rs 141.87 crore in the quarter ended March 2025 as against Rs 97.94 crore during the previous quarter ended March 2024. Sales rose 21.05% to Rs 649.55 crore in the quarter ended March 2025 as against Rs 536.60 crore during the previous quarter ended March 2024. For the full year,net profit rose 3.13% to Rs 485.63 crore in the year ended March 2025 as against Rs 470.89 crore during the previous year ended March 2024. Sales rose 4.54% to Rs 2386.88 crore in the year ended March 2025 as against Rs 2283.21 crore during the previous year ended March 2024. ParticularsQuarter EndedYear EndedMar. 2025Mar. 2024% Var.Mar. 2025Mar. 2024% Var. Sales649.55536.60 21 2386.882283.21 5 OPM %30.5526.36 -28.6029.53 - PBDT207.27144.21 44 714.74684.74 4 PBT191.30129.68 48 654.13631.29 4 NP141.8797.94 45 485.63470.89 3 Powered by Capital Market - Live
Alivus Life Sciences will hold a meeting of the Board of Directors of the Company on 15 May 2025.Powered by Capital Market - Live
Alivus Life Sciences has allotted 92,096 equity shares under ESOS on 30 April 2025. Consequent to the allotment, the paid up equity share capital has increased to 12,26,29,148 equity shares of Rs. 2 each aggregating to Rs. 24,52,58,296/-. Powered by Capital Market - Live
Net profit of Alivus Life Sciences rose 15.32% to Rs 136.96 crore in the quarter ended December 2024 as against Rs 118.77 crore during the previous quarter ended December 2023. Sales rose 12.05% to Rs 641.84 crore in the quarter ended December 2024 as against Rs 572.80 crore during the previous quarter ended December 2023. ParticularsQuarter EndedDec. 2024Dec. 2023% Var. Sales641.84572.80 12 OPM %29.6530.13 - PBDT200.31173.87 15 PBT185.15160.69 15 NP136.96118.77 15 Powered by Capital Market - Live
Profit before tax (PBT) climbed 15.22% YoY to Rs 185.14 crore in Q3 FY25. For Q3FY25, EBITDA was at Rs 200.8 crore, a growth of 15.2% YoY. EBITDA margin stood at 31.3%, up 90 bps YoY. On segmental front, the revenue from Generic API grew by 16.9% YoY to Rs 596.6 crore in Q3 FY25 while revenue from CDMO declined 14.29% YoY to Rs 30 crore in Q3 FY25. Yasir Rawjee, MD & CEO, Alivus Life Sciences, said, 'The start of the new year marks a notable shift for us as we transition to Alivus Life Sciences. I am pleased to report that our Q3 performance reflects this renewed energy, with growth across both GPL and Non-GPL segments. Geographically, regions like India, Europe, ROW and Japan contributed to the growth. Alivus Life Sciences (Formerly Glenmark Life Sciences) is a leading developer and manufacturer of select, high-value, non-commoditized, active pharmaceutical ingredients (APIs) in chronic therapeutic areas such as cardiovascular disease, central nervous system disease, pain management and diabetes. It has a diversified portfolio of 161 molecules & supplies its products to customers in India, Europe, North America, Latin America, Japan, and the Rest of the World (RoW).Powered by Capital Market - Live
Avantel Ltd, Sunteck Realty Ltd, Spandana Sphoorty Financial Ltd and Jai Corp Ltd are among the other gainers in the BSE's 'A' group today, 21 January 2025.Alivus Life Sciences Ltd surged 6.82% to Rs 1178.4 at 11:46 IST. The stock was the biggest gainer in the BSE's 'A' group. On the BSE, 11436 shares were traded on the counter so far as against the average daily volumes of 5071 shares in the past one month. Avantel Ltd spiked 6.10% to Rs 143.6. The stock was the second biggest gainer in 'A' group. On the BSE, 3.06 lakh shares were traded on the counter so far as against the average daily volumes of 1.35 lakh shares in the past one month. Sunteck Realty Ltd soared 5.43% to Rs 517.7. The stock was the third biggest gainer in 'A' group. On the BSE, 1.38 lakh shares were traded on the counter so far as against the average daily volumes of 12899 shares in the past one month. Spandana Sphoorty Financial Ltd advanced 4.99% to Rs 366.95. The stock was the fourth biggest gainer in 'A' group. On the BSE, 2.38 lakh shares were traded on the counter so far as against the average daily volumes of 1.94 lakh shares in the past one month. Jai Corp Ltd gained 4.22% to Rs 157. The stock was the fifth biggest gainer in 'A' group. On the BSE, 71599 shares were traded on the counter so far as against the average daily volumes of 2.64 lakh shares in the past one month. Powered by Capital Market - Live
Glenmark Life Sciences announced its change of identity to Alivus Life Sciences, marking an exciting new chapter in its journey. This is consequent to the acquisition by Nirma, a diversified conglomerate with interest in consumer products, chemicals, and pharmaceuticals. The change is reflective of the company's evolving vision aimed at further strengthening its global presence and a commitment to providing innovative solutions in the API and CDMO space. The new identity, Alivus Life Sciences, represents vitality and growth with a renewed focus. It embodies the optimism and transformation the company is embracing as it enters the next phase of its journey. The official website is now alivus.com. Powered by Capital Market - Live
Glenmark Life Sciences will hold a meeting of the Board of Directors of the Company on 23 January 2025.Powered by Capital Market - Live
Glenmark Life Sciences has been renamed Alivus Life Sciences with effect from 17 December 2024. Powered by Capital Market - Live
Over the last 5 years, revenue has grown at a yearly rate of 20.95%, vs industry avg of 9.02%
Over the last 5 years, market share increased from 0.4% to 0.6%
Over the last 5 years, net income has grown at a yearly rate of 19.21%, vs industry avg of 15.29%